<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03917381</url>
  </required_header>
  <id_info>
    <org_study_id>GCT1046-01</org_study_id>
    <nct_id>NCT03917381</nct_id>
  </id_info>
  <brief_title>GEN1046 Safety Trial in Patients With Malignant Solid Tumors</brief_title>
  <official_title>First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmab</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genmab</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the trial is to evaluate the safety of GEN1046 in patients with malignant
      solid tumors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is an open-label, multi-center safety trial of GEN1046. The trial consists of two
      parts, a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase
      2a)). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose
      (RP2D) has been determined.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 14, 2019</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The starting dose is administered as a flat dose. Dose escalation steps are based on safety data</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (DLT)</measure>
    <time_frame>DLTs are assessed during the first cycle (21 days) in each cohort]</time_frame>
    <description>to determine maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>AEs are collected throughout the study and up to 2 months after last subject last treatment</time_frame>
    <description>Incidence of treatment-emergent adverse events as assessed by CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety laboratory parameters (hematology, biochemistry, coagulation, endocrines)</measure>
    <time_frame>Safety laboratory data are collected throughout the study and up to 2 months after last subject last treatment</time_frame>
    <description>Laboratory parameters graded by CTCAE v5.0</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Endometrial Carcinoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GEN1046 Open label, single arm trial where GEN1046 will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEN1046</intervention_name>
    <description>GEN1046 will be administered intravenously once every 21 days. The dose levels will be determined by the starting dose and the escalation steps taken in the trial.</description>
    <arm_group_label>Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        For Dose Escalation:

        • Have a histologically or cytologically confirmed non-CNS solid tumor that is metastatic
        or unresectable and for whom there is no available standard therapy

        For Expansion:

        • Have histologically or cytological confirmed diagnosis of relapsed or refractory,
        advanced and/or metastatic NSCLC, EC, UC, TNBC, SCCHN, or cervical cancer who are not
        anymore candidates for standard therapy

        For Both Dose Escalation and Expansion

          -  Have measurable disease according to RECIST 1.1

          -  Have Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Have an acceptable hematological status

          -  Have acceptable liver function

          -  Have an acceptable coagulation status

          -  Have acceptable renal function

        Exclusion Criteria:

          -  Have uncontrolled intercurrent illness, including but not limited to:

               -  Ongoing or active infection requiring intravenous treatment with antiinfective
                  therapy

               -  Symptomatic congestive heart failure (Grade III or IV as classified by the New
                  York Heart Association), unstable angina pectoris or cardiac arrhythmia

               -  Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or
                  diastolic blood pressure ≥ 100 mmHg, despite optimal medical management

               -  Ongoing or recent evidence of autoimmune disease

               -  History of irAEs that led to prior checkpoint treatment discontinuation

               -  Prior history of myositis, Guillain-Barré syndrome, or myasthenia gravis of any
                  grade

               -  History of chronic liver disease or evidence of hepatic cirrhosis

               -  History of non-infectious pneumonitis that has required steroids or currently has
                  pneumonitis

               -  History of organ allograft (except for corneal transplant) or autologous or
                  allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to
                  the first dose of GEN1046

               -  Serious, non-healing wound, skin ulcer (of any grade), or bone fracture

          -  Any history of intracerebral arteriovenous malformation, cerebral aneurysm, new
             (younger than 6 months) or progressive brain metastases or stroke

          -  Prior therapy:

               -  Radiotherapy: Radiotherapy within 14 days prior to first GEN1046 administration.
                  Palliative radiotherapy will be allowed.

               -  Treatment with an anti-cancer agent (within 28 days or after at least 5
                  half-lives of the drug, whichever is shorter), prior to GEN1046 administration.
                  Accepted exceptions are bisphosphonates (e.g., pamidronate, zoledronic acid,
                  etc.) and denosumab

          -  Toxicities from previous anti-cancer therapies that have not adequately resolved
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Genmab Trial Information</last_name>
    <phone>+4570202728</phone>
    <email>clinicaltrials@genmab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia M LoRusso</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Sharma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus RHCC - Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Maurice-Dror</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravit Geva</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center, Ramat Gan</name>
      <address>
        <city>Tel HaShomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eytan Ben-Ami</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall dHebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Garralda Cabanas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>START Madrid-FJD, Hospital Fundación Jiménez Díaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Moreno</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Ponce</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>START Madrid-CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiliano Calvo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Melero</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2019</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

